Company History

Patrys listed on the Australian Stock Exchange (ASX) in 2007 to develop new antibody therapies for the treatment of cancer. In 2016, Patrys secured an exclusive, worldwide license from Yale University for the use of deoxymab antibodies as human therapeutic agents for treatment and management of cancer.

Board of Directors

Our Board is comprised of respected global leaders in clinical research, specialist oncology treatment development, and commercialisation.

John Read

Chairman, BSc (Hons), MBA, FAICD

Mr. Read is an experienced Chairman and Director in public, private and government organisations. Through his extensive career in venture capital, private equity and commercialisation he has gained a depth of experience in the formation and growth of emerging companies with an emphasis on commercial entities that provide broad societal benefits.

He is currently the Chairman of CVC Limited (ASX: CVC) and previously Chairman of Eildon Capital Limited (ASX:EDC) from 2013 to 2016, Pro-Pac Packaging Limited (ASX:PPG) from 2005 to 2010, The Environmental Group Limited (ASX:EGL) from 2001 to 2012 and The Central Coast Water Corporation from 2011 to 2014.

James Campbell

Managing Director & Chief Executive Officer, BSc (Hons), PhD, MBA, GAICD

Dr. Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies.

Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS), where, as a member of the executive team he helped transform a research-based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M.

Dr. Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with successful capital raising and partnering negotiations. Dr. Campbell sits on the Advisory Board of Deakin University’s Centre for Innovation in Mental and Physical Health and Clinical Treatment (IMPACT). Dr. Campbell is a Non-Executive Director of Prescient Therapeutics Limited (ASX:PTX).

Michael Stork

Non-Executive Director, BBA

Mr. Stork is the Managing Director of Stork Holdings Ltd, an Investment Holding company active in the Canadian technology startup sector. Mr. Stork was until early this year active on the Board of Governors of the University of Waterloo and is the Chairman of the Waterloo Accelerator Centre, a technology company incubator affiliated with the University.

He is currently the Chairman of Spartan Biosciences Inc., an Ottawa based DNA analytics company, the Chairman of Dejero Labs Inc., a Waterloo based broadcast technology company, and active on the Boards of a number of other leading Canadian technology startup companies.

Suzy Jones

Non-Executive Director

Ms. Jones is Founder and Managing Partner of DNA Ink LLC, a life sciences advisory firm in San Francisco with clients in the United States and Europe. DNA Ink provides corporate strategic guidance to its clients that support corporate growth.

Prior to starting her own firm, Ms. Jones spent 20 years at Genentech where she served in many roles including Interim Head of Partnering, Head of Business Development, Senior Project Manager and Research Associate. She managed several products teams during this time including Rituxan, the first monoclonal antibody launched to treat cancer. Ms. Jones has very extensive networks within the pharmaceutical and biotech companies and VC community in North America.

Ms. Jones is a Non-Executive Director of Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.

Pamela M. Klein

Non-Executive Director, BSc, MD

Dr. Pamela M. Klein completed her medical training at Stritch School of Medicine, Loyola University in Chicago, followed by internal medicine training at Cedars-Sinai, Los Angeles, prior to spending 7 years working at the U.S. National Cancer Institute.

Dr. Klein then moved to Genentech where, as Vice President, Development she led the development of a large portfolio of drugs including all the HER (Herceptin, Tarceva, Perjeta), Apoptosis (antibodies and small molecules) and Hematology compounds. After Genentech Dr. Klein was appointed to the position of Chief Medical Officer of Intellikine where she built the clinical development capability and brought multiple early compounds from laboratory to clinic prior to Intellikine before being acquired by Millennium/Takeda.

Currently, Dr. Klein currently serves as an advisor to a range of different biotech and investment companies, with roles on Scientific Advisory Boards and Corporate Boards as well as broader advisory roles.


Our Management Team are long-standing employees and highly capable professionals, with a cross-section of skills and experience targeted to our needs.

Stefan Ross

Company Secretary, BBus (Accounting)

Stefan Ross has over 10 years of experience in accounting and secretarial services for ASX Listed companies. His extensive experience includes ASX compliance, corporate governance control and implementation, statutory financial reporting, shareholder meeting requirements, capital raising management, preparation of prospectus’, and board and secretarial support. Mr Ross has a Bachelor of Business, majoring in Accounting.

Deanne Greenwood

Vice President Business Development & Intellectual Property, BSc (Hons), PhD, MBA, GAICD

Dr. Greenwood joined Patrys in 2008 and has held various roles during that time. At Patrys, Dr. Greenwood’s efforts are focused on commericalisation of the IgM and Deoxymab assets and management of the extensive intellectual property portfolio. She has extensive experience related to the R&D drug development, relationship management, contracts and grants. Dr. Greenwood led the negotiations with Hefei Co-source Biomedical Co. LTD, a Chinese based company which has taken an exclusive license to PAT-SC1.

Prior to joining Patrys, Dr. Greenwood spent 10-years in academia conducting immunology research in the areas of vaccine development and autoimmunity, with the last four years at the Centre for Animal Biotechnology, The University of Melbourne. Dr. Greenwood has a PhD degree in Immunology from the Monash University, Masters of Business Administration (Technology) from La Trobe University and is a graduate of the Australian Institute of Company Directors (GAICD). Dr. Greenwood is a co-author on 11 publications on immunological related topics. Dr. Greenwood recently completed a postgraduate course at Harvard Business School focusing on negotiation and decision making.

Valentina Dubljevic

Vice President Scientific & Clinical Development, MBB, BSc, GAICD

Ms. Dubljevic joined Patrys in June 2012 and is responsible for the pre-clinical and clinical development of Patrys’ products. Ms. Dubljevic brings more than 20 years of scientific and commercial experience in the areas of anti- cancer therapies, vaccine development, and diagnostics.

Prior to joining Patrys, she worked at the Monash University conducting research on malaria vaccine development; at Cytopia Limited developing small molecule anti-cancer drugs and at Monash Institute of Medical Research (MIMR) developing antibody therapies for cancer. She has extensive experience related to the drug development, management of pre-clinical studies, manufacturing, regulatory and clinical operations, contracts and project management and has co-authored multiple scientific papers and grants.

Ms. Dubljevic holds a Bachelor of Biomedical Science degree from Griffith University, Brisbane, a Masters in Biotechnology and Business degree from RMIT and is a graduate of the Australian Institute of Company Directors (GAICD).

Scientific Advisory Board

Our scientific advisors are globally sought-after professionals, leveraging focused expertise to guide our research and development.

Peter Ordentlich, BSc, PhD

Dr Peter Ordentlich completed a PhD in Immunology at the University of Pennsylvania and a Post-Doc at the Salk Institute for Biological Studies before joining X-Ceptor Therapeutics, a discovery stage biotechnology company focused on the identification of novel therapeutics for cardiovascular and oncology indications. Dr Ordentlich spent five years as a research scientist leading multiple lead discovery and optimization projects at X-Ceptor Therapeutics, which was acquired by Exelixis in 2004.

In 2005 Dr Ordentlich co-founded Syndax Pharmaceuticals, a NASDAQ-listed, clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies with three clinical stage assets, where he is currently the Chief Scientific Officer.

Allen Ebens, BSc, PhD

Dr. Allen Ebens has more than 25 years of industry research and drug development experience focused in the areas of oncology, hematology, hematology/oncology, and immunology.

He has worked in a variety of therapeutic platforms including small molecule discovery, conventional antibody therapies, antibody-drug conjugates, T-cell recruiting bispecific antibodies and CAR-T and TCR-based cellular therapies. Dr. Ebens started his professional career at Exelixis and went on to work at Genentech, Juno, NGM Bio, and is currently Chief Scientific Officer at Vera Therapeutics.

Over the course of his career he has invented and developed or made very substantial contributions to more than a dozen molecules that have gone on to clinical testing, including polatuzumab vedotin, an ADC which was approved for use in lymphoma patients by the FDA in 2019.